Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...
We just covered the 14 Best Defensive Stocks to Invest In Now and Gilead Sciences, Inc. (NASDAQ:GILD) ranks 4th on this list. Gilead Sciences, Inc. (NASDAQ:GILD) has transitioned away from its ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results